biostudies-literatureHaskett DGNIBIB NIH HHSNHLBI NIH HHS1814-1822.e3https://www.ebi.ac.uk/biostudies/studies/S-EPMC6200342biostudies-literatureUnknown156(5)<h4>Objective</h4>Tissue-engineered vascular grafts containing adipose-derived mesenchymal stem cells offer an alternative to small-diameter vascular grafts currently used in cardiac and lower-extremity revascularization procedures. Adipose-derived, mesenchymal stem cell-infused, tissue-engineered vascular grafts have been shown to promote remodeling and vascular homeostasis in vivo and offer a possible treatment solution for those with cardiovascular disease. Unfortunately, the time needed to cultivate adipose-derived mesenchymal stem cells remains a large hurdle for tissue-engineered vascular grafts as a treatment option. The purpose of this study was to determine if stromal vascular fraction (known to contain progenitor cells) seeded tissue-engineered vascular grafts would remain patentThe Journal of thoracic and cardiovascular surgeryAn exploratory study on the preparation and evaluation of a "same-day" adipose stem cell-based tissue-engineered vascular graft.PMC6200342T32 HL098036R21 EB016138R01 HL130077R21 HL130784Luketich SKKokai LEWagner WRHaskett DGD'Amore ALorentz KLJosowitz ADRubin JPMarra KGVorp DASaleh KSWeinbaum JSfalseAn exploratory study on the preparation and evaluation of a "same-day" adipose stem cell-based tissue-engineered vascular graft.<h4>Objective</h4>Tissue-engineered vascular grafts containing adipose-derived mesenchymal stem cells offer an alternative to small-diameter vascular grafts currently used in cardiac and lower-extremity revascularization procedures. Adipose-derived, mesenchymal stem cell-infused, tissue-engineered vascular grafts have been shown to promote remodeling and vascular homeostasis in vivo and offer a possible treatment solution for those with cardiovascular disease. Unfortunately, the time needed to cultivate adipose-derived mesenchymal stem cells remains a large hurdle for tissue-engineered vascular grafts as a treatment option. The purpose of this study was to determine if stromal vascular fraction (known to contain progenitor cells) seeded tissue-engineered vascular grafts would remain patent2018-01-01T00:00:00Z2018 Nov2025-04-04T13:30:19.813Z2019-11-07T08:01:44ZS-EPMC62003423005719210.1016/j.jtcvs.2018.05.120